No Data
Coherus Out Licenses Canadian Rights to Cancer Drug Loqtorzi
Express News | Coherus BioSciences - Apotex Agreed to Pay to Co USD Equivalent of up to Aggregate of up to $51.5 Mln Canadian Dollars in Milestone Payments
Express News | Coherus BioSciences Inc - Apotex Agreed to Pay to Company an Upfront Payment of $6.25 Mln United States Dollars
Express News | Coherus BioSciences Inc - Has Granted to Apotex an Exclusive License Under Co's Rights to Toripalimab to Commercialize Toripalimab Within Canada
Express News | Coherus BioSciences Inc - on June 27, Entered Into an Exclusive License and Distribution Agreement With Apotex, Inc
Baird Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Cuts Target Price to $8
Baird analyst Colleen M. Kusy maintains $Coherus BioSciences(CHRS.US)$ with a buy rating, and adjusts the target price from $9 to $8.According to TipRanks data, the analyst has a success rate of 30.2%